Decisions are being made to withdraw from Korea one after another, citing the weakening profitability of Parkinson's disease original treatment drugs, for which generics have appeared. Early this year, following Roche Korea's Madopar, Boehringer Ingelheim Korea's Mirapex ER also decided to stop supplying. The problem is that existing patients have a distrust of generic drugs, so there is a concern about a treatment gap if the supply of the original drug is discontinued.

According to the industry on the 19th, Boehringer Ingelheim Korea recently informed the retailer that it would stop supplying Mirapex ER. Accordingly, Mirapex ER 0.375mg is expected to be sold out by July 31 next year, Mirapex ER 1.5mg b